A retrospective analysis investigating the safety and efficacy of Cenobamate (CNB) in drug resistant patients with genetic generalized epilepsies (GGE) or combined generalized and focal epilepsies (CGFE) which includes developmental and epileptic encephalopathies (DEEs)
Latest Information Update: 27 Jan 2023
At a glance
- Drugs Cenobamate (Primary)
- Indications Generalised epilepsy; Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 Jan 2023 New trial record
- 06 Dec 2022 Results presented at the 76th Annual Meeting of the American Epilepsy Society